[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t-lgl-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t-lgl-leukemia":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,86,107,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100275317","registry-of-the-german-cll-study-group-100275317",false,"NCT02863692","Registry of the German CLL Study Group","Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation","CLL-Registry","Inclusion Criteria (all must apply)\n\n1. Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's transformation\n2. 18 years of age or older\n3. Signed, written informed consent\n4. Presence of one or more of the following disease situations:\n\n   * Newly diagnosed patients without treatment indication (eligible for watch and wait Approach Treatment within a clinical trial according to the AMG or status post participation in a clinical Trial)\n   * Treatment with standard therapies approved for the eligible entities or status post treatment (outside of clinical trials)\n   * Referral for evaluation the indication for HSCT\n   * Relapsed disease status (even if first diagnosis was prior to activation of the registry)\n\nExclusion Criteria\n\n1. Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HCL or Richter's transformation\n2. Cerebral dysfunction, legal incapacity","ALL","18 Years",{"count":20,"type":21},8000,"ESTIMATED","25 Years","OBSERVATIONAL","Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T\u002FNatural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation",[26,27,28,29,30,31,32,33],"CLL","SLL","HCL","Richter´s Transformation","Leukemia, Prolymphocytic, B-Cell","Leukemia, Prolymphocytic, T-Cell","T-LGL Leukemia","NK-LGL Leukemia",[26,35,36,27,37,28,29],"B-PLL","T-PLL","T-NK-LGL","RECRUITING","2025-12-01",{"date":41,"type":42},"2025-12-08","ACTUAL",{"date":44,"type":4},"2013-08",{"date":46,"type":21},"2026-12",{"name":48,"class":49},"German CLL Study Group","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":73,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100571162","phase-2-jak1-inhibitor-golidocitnib-for-the-treatment-of-relapsedrefractory-indolent-tnk-cell-lymphomas-100571162","NCT06716658","JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed\u002FRefractory Indolent T\u002FNK-cell Lymphomas","Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed\u002FRefractory Indolent T\u002FNK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years, with no restrictions on gender;\n2. Histologically confirmed relapsed\u002Frefractory (R\u002FR) indolent T\u002FNK-cell; lymphoma that has failed at least one systemic therapy or is intolerant to such treatment and\u002For currently has no effective standard treatment options;\n3. The patient meets the criteria for appropriate therapeutic indications;\n4. ECOG performance status of 0-2;\n5. Adequate organ function, defined as: Total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; Blood urea nitrogen (BUN)\u002FUrea and creatinine (Cr) ≤ 1.5 × ULN; Left ventricular ejection fraction (LVEF) ≥ 50%; Fridericia-corrected QT interval (QTcF): \\\u003C 450 ms for males, \\\u003C 470 ms for females;\n6. An expected survival time of at least 3 months;\n7. Male and female subjects of childbearing potential must agree to use effective contraception throughout the study period and for 6 months after the last dose of the investigational drug;\n8. A washout period of ≥ 4 weeks since receiving any prior antitumor therapies (including radiotherapy, chemotherapy, hormone therapy, surgery, or molecular targeted therapy) before participating in this study;\n9. The subject has not participated in any other clinical trial within 1 month prior to enrollment;\n10. The subject agrees to and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Subjects who have previously used any JAK inhibitors;\n2. Subjects with clinical conditions such as dysphagia, malabsorption, or other chronic gastrointestinal diseases that may interfere with compliance and\u002For absorption of the study drug;\n3. Subjects with active viral, bacterial, or fungal infections requiring treatment (e.g., pneumonia);\n4. Subjects with HBV or HCV infections, defined as HBsAg and\u002For HBcAb positivity and HBV DNA copy number ≥ the upper limit of normal (ULN), or acute or chronic active hepatitis C (HCV antibody-positive);\n5. Subjects with a history of immunodeficiency, including those who are HIV-positive, or those with other acquired or congenital immunodeficiency diseases, a history of organ transplantation, or a history of allogeneic bone marrow or hematopoietic stem cell transplantation;\n6. Subjects who have undergone autologous hematopoietic stem cell transplantation within 90 days prior to the first dose of study treatment;\n7. Subjects with severe or uncontrolled cardiovascular diseases;\n8. Subjects with severe concomitant diseases that pose a significant risk to patient safety or, in the investigator's judgment, may interfere with the completion of the study (e.g., uncontrolled hypertension, diabetes, or thyroid disorders);\n9. Pregnant or breastfeeding female subjects, or baseline positive pregnancy test results in women of childbearing potential;\n10. Subjects with a history of other malignancies diagnosed or treated within the past 5 years;\n11. Any other conditions that, in the investigator's opinion, render the subject unsuitable for participation in the study.",{"count":59,"type":21},48,"INTERVENTIONAL",[62],"PHASE2","Indolent T\u002FNK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T\u002FNK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T\u002FNK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed\u002Frefractory indolent T\u002FNK-cell lymphomas. Patients will be treated with Golidocitnib, with an expected overall response rate of 60% for JAK1 inhibitor Golidocitnib treatment.",[65,33,32,66,67,68,69,70,71,72],"Lymphoma, T-Cell","Cutaneous T Cell Lymphoma","Cutaneous T Cell Lymphoma (CTCL)","Large Granular Lymphocyte Leukemia","Large Granular Lymphocytic Leukemia","Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract","Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma","Mycosis Fungoides",[74,75],"Indolent T\u002FNK-cell lymphomas","JAK1 inhibitor","2025-11-14",{"date":78,"type":42},"2025-11-18",{"date":80,"type":42},"2024-12-25",{"date":82,"type":21},"2028-11-15",{"name":84,"class":49},"Institute of Hematology & Blood Diseases Hospital, China",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":60,"phases":94,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":50},"100556858","phase-2-thalidomide-for-the-symptomatic-large-granular-lymphocytic-leukemia-100556858","NCT06530576","Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia","The Efficacy of Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Phase Ⅱ Multicenter Clinical Trial From China","Inclusion Criteria:\n\n1. The patient fully understands the study, voluntarily participates, and signs the informed consent form (ICF);\n2. The patient must meet the diagnostic criteria for LGLL;\n3. The patient can be of any gender, aged 18 years or older;\n4. The patient is either untreated or not properly treated previously, or has poor efficacy (not reaching PR) or relapsed after being treated with regimens not based on methotrexate\u002Fthalidomide;\n5. The patient has indications for LGLL treatment, meeting at least one of the following criteria:\n\n   1. ANC \\\u003C 0.5 × 10\\^9\u002FL, or neutropenia with recurrent infections\n   2. HGB \\\u003C 100 g\u002FL or requiring red blood cell transfusions for maintenance\n   3. PLT \\\u003C 50 × 10\\^9\u002FL\n   4. Concurrent autoimmune disease requiring treatment\n   5. Symptomatic splenomegaly\n   6. Severe B symptoms (unexplained fever, temperature over 38°C; night sweats; weight loss of 10% or more within six months)\n   7. Pulmonary hypertension;\n6. ECOG score of 0-2;\n7. The patient's expected survival period is 6 months or more.\n\nExclusion Criteria:\n\n1. Unable to understand or follow the study procedures;\n2. Diagnosed or treated for malignancies other than LGLL within the past five years;\n3. Non-lymphoma-related liver or kidney function impairment: ALT \\> 3 times the upper limit of normal (ULN), AST \\> 3 times the ULN, total bilirubin (TBIL) \\> 2 times the ULN, serum creatinine clearance \\\u003C 30 ml\u002Fmin;\n4. Other serious medical conditions that could affect the study (e.g., uncontrolled diabetes, gastric ulcer, other serious heart or lung diseases), with the judgment resting with the investigator;\n5. Caprini thrombosis analysis score indicating high risk (Appendix 2);\n6. Known history of HIV infection or active HBV infection, or any uncontrolled active systemic infection requiring intravenous antibiotics; Note: Active HBV infection is defined as: a. HBV DNA ≥ 2000 IU\u002Fml; b. ALT ≥ 2 times the ULN; c. Exclusion of hepatitis due to the disease itself, drugs, or other causes. All three conditions must be met. If a patient initially has active HBV infection and turns into inactive HBV infection after anti-HBV treatment, they can be included in the study provided they receive adequate anti-HBV treatment.\n7. Patients who have undergone major surgery (excluding lymph node biopsy) within the past 14 days or are expected to undergo major surgery during the treatment;\n8. Pregnant or breastfeeding women, and women of childbearing age who are not using contraception;\n9. Hypersensitivity to the drugs or their components used in the study.",{"count":59,"type":21},[62],"There is currently no standard first-line treatment for LGLL. The investigators used the TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2020, enrolling a total of 54 patients and achieving an overall response rate (ORR) of 88.9% and a complete response (CR) rate of 75.9%. To further explore this hypothesis, the investigators designed this study to observe the efficacy of thalidomide monotherapy in patients with symptomatic LGLL. The investigators speculate that thalidomide plays a major role in the significant improvement of the TPM regimen compared to the MTX regimen.\n\nPatients with LGLL are treated with thalidomide at 50 to 100 mg. If the desired response is not achieved at specific time points, methotrexate is added. Thalidomide monotherapy is administered for up to 3 courses, and the TM regimen can also be used for up to 3 courses. The overall response rate with thalidomide monotherapy serves as the primary study endpoint.",[32,33],[98,99,100],"Large granular lymphocyte leukemia","Thalidomide","Overall response rate",{"date":78,"type":42},{"date":103,"type":42},"2024-08-10",{"date":105,"type":21},"2027-07-01",{"name":84,"class":49},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":60,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":50},"100556856","phase-2-pi3k-inhibitors-for-the-treatment-of-relapsedrefractory-indolent-tnk-cell-lymphomas-100556856","NCT06530550","PI3K Inhibitors for the Treatment of Relapsed\u002FRefractory Indolent T\u002FNK-cell Lymphomas","Exploratory Clinical Study of PI3K Inhibitors in the Treatment of Relapsed\u002FRefractory Indolent T\u002FNK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial","Inclusion Criteria:\n\nthe proportion of patients whose tumors have not progressed after treatment over a specific period of time. Specifically, DCR includes the percentage of patients who achieve complete response (CR), partial response (PR), and stable disease (SD).\n\nExclusion Criteria:\n\nHere is the translated text:\n\n1. Subjects who have previously used any PI3K inhibitors;\n2. Clinical conditions of dysphagia, malabsorption, or other chronic gastrointestinal diseases that may interfere with compliance and\u002For absorption of the study drug;\n3. Unable to discontinue medications that may prolong the QT interval (such as antiarrhythmic drugs) during the study period;\n4. Active viral, bacterial, or fungal infections requiring treatment (e.g., pneumonia);\n5. HBV or HCV infection (defined as HBsAg and\u002For HBcAb positive with HBV DNA copy number ≥ upper limit of normal reference value) or acute or chronic active hepatitis C (HCV) antibody positive;\n6. History of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation, or history of allogeneic bone marrow or hematopoietic stem cell transplantation;\n7. Received autologous hematopoietic stem cell transplantation within 90 days before the first dose of study treatment;\n8. Presence of severe or uncontrolled cardiovascular disease;\n9. Presence of severe concomitant diseases that endanger patient safety or are deemed by the investigator to affect the completion of the study (e.g., uncontrolled hypertension, diabetes, thyroid disease);\n10. Pregnant or breastfeeding female patients, or baseline pregnancy test positive for women of childbearing potential;\n11. Diagnosed or treated for other malignancies within the past 5 years;\n12. Any other condition that the investigator deems unsuitable for participation in the study.",{"count":115,"type":21},51,[62],"Indolent T\u002FNK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T\u002FNK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T\u002FNK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed\u002Frefractory indolent T\u002FNK-cell lymphomas. Patients will be treated with Linperlisib or Duvelisib, with an expected overall response rate of 60% for PI3K inhibitor treatment.",[65,33,32],[74,120],"PI3K inhibitor","2025-08-11",{"date":123,"type":42},"2025-08-12",{"date":103,"type":42},{"date":126,"type":21},"2028-07-10",{"name":84,"class":49},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":50},"100594463","national-longitudinal-cohort-of-hematological-diseases-large-granular-lymphocytic-leukemia-100594463","NCT07019766","National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia","NICHE-LGLL","Inclusion Criteria:\n\n* Subjects diagnosed with LGLL.\n* Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000.\n\nExclusion Criteria:\n\n* Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities).\n* Subject with alcohol or drug dependence that may reduce their compliance with the study.\n* Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.",{"count":136,"type":21},9999,"Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology.\n\nThe objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China.\n\n1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors.\n2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics\n3. Assess treatment patterns and real-world effectiveness in LGLL patients.\n4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality\n5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.",[32,33],[140,141],"Treatment patterns","Hematologic response","2025-06-15",{"date":144,"type":42},"2025-06-17",{"date":146,"type":42},"2000-01-01",{"date":148,"type":21},"2070-12-31",{"name":84,"class":49}]